Transfer-pricing treatment of ITeS margins excludes pass-through tax recoveries and separate delayed-receivables interest after working-capital adjust...
Capacity-utilisation adjustments under TNMM can neutralise substantiated COVID-related idle costs where underutilisation materially affects profitabil...
TNMM functional comparability requires excluding rice manufacturers from a pure Basmati rice trader's benchmark and recognising operating export recei...
Working-capital adjustment subsumes delayed-receivable effects in TNMM benchmarking of captive software-development services, avoiding separate notion...
Transfer-pricing comparability requires exclusion of financially illogical super-profit comparables and correction of unsupported annual-report and ma...
Charitable character assessment preserves Section 80G approval despite inclusive spiritual teachings and incidental religious expenditure within the s...
Penalty proceedings for cash-loan acceptance require assessment proceedings and recorded Assessing Officer satisfaction; absent these, the proceedings...
Page of 4828
Press 'Enter' after typing page number.
161 to 180 of 96556 Results
❮
❯
❯❯
0 / 200
Expand Note
Add to Folder
No Folders have been created
+
Are you sure you want to delete "My most important" ?
Under Customs Act s.25(1), MoF amended notification 16/2017-Customs to expand customs duty exemptions for specified pharmaceutical drugs distributed through Patient Assistance Programs (PAPs). The amendment adds 37 new pharmaceutical products (entries 53-89) from multiple manufacturers including MSD Pharmaceuticals, Pfizer, Novartis, AstraZeneca, Johnson & Johnson, Merck, Takeda, GSK, and Roche. The exempted drugs include treatments for cancer, rare diseases, and autoimmune conditions. The notification takes effect from February 2, 2025, demonstrating government's commitment to improve access to specialized medications through manufacturer-sponsored patient support programs.
Under Customs Act s.25(1), MoF amended notification 16/2017-Customs to expand customs duty exemptions for specified pharmaceutical drugs distributed through Patient Assistance Programs (PAPs). The amendment adds 37 new pharmaceutical products (entries 53-89) from multiple manufacturers including MSD Pharmaceuticals, Pfizer, Novartis, AstraZeneca, Johnson & Johnson, Merck, Takeda, GSK, and Roche. The exempted drugs include treatments for cancer, rare diseases, and autoimmune conditions. The notification takes effect from February 2, 2025, demonstrating government's commitment to improve access to specialized medications through manufacturer-sponsored patient support programs.
Note: It is a system-generated summary and is for quick reference only.